Plerixafor

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Multiple Myeloma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Promotion of mobilisation of haematopoietic stem cells into peripheral blood for autologous peripheral blood stem cell transplantation
Product first approved 2016Outside this platform's coveragePMDA
EU
  • With G-CSF to mobilise haematopoietic stem cells in patients with lymphoma and multiple myeloma whose cells mobilise poorly
Product first approved 2009EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (6)
Multiple Myeloma
NCT01146834 · Weill Medical College of Cornell University
2011-03 – 2019-02-04 · Multiple Myeloma
What this study did
NCT01301963 · Case Comprehensive Cancer Center
2011-07 – 2013-06 · Refractory Multiple Myeloma
What this study did
Other / comorbidity
NCT00103610 · Genzyme, a Sanofi Company
2005-01 – 2007-12 · Lymphoma, Non-Hodgkin
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02231879 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-10-14 – 2021-02-24 · Myelokathexis, Infections, Neutropenia, Warts, Hypogammaglobulinemia
What this study did
Phase 2 (60)
Multiple Myeloma
NCT07188090 · Thomas Jefferson University
2025-10-16 – 2028-06 · Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
What this study did
NCT05007652 · Kyowa Kirin Co., Ltd.
2021-09-01 – 2022-10-25 · Multiple Myeloma and Malignant Lymphoma
What this study did
NCT04552743 · Surbhi Sidana, MD
2020-10-05 – 2022-06-30 · Multiple Myeloma
What this study did
NCT01547806 · National Cancer Institute (NCI)
2012-02-22 – 2018-01-11 · Plasma Cell Myeloma, Multiple Myeloma
What this study did
NCT02682953 · University of Maryland, Baltimore
2015-10 – 2017-08 · Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma, Lymphoma
What this study did
NCT01158118 · Washington University School of Medicine
2011-04-01 – 2016-12-31 · Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Multiple Myeloma
What this study did
NCT02098109 · Washington University School of Medicine
2014-08-20 – 2016-09-18 · Multiple Myeloma, Lymphoma, Non-Hodgkin
What this study did
NCT01339572 · University of Florida
2011-04 – 2015-11 · Non-Hodgkin's Lymphoma, Multiple Myeloma
What this study did
NCT00998049 · Mayo Clinic
2009-12 – 2015-04 · Multiple Myeloma, Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
NCT01037517 · CancerCare Manitoba
2010-01 – 2013-08 · Multiple Myeloma, Lymphoma
What this study did
NCT00901225 · Duke University
2009-05 – 2013-05 · Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
What this study did
NCT00665314 · Genzyme, a Sanofi Company
2007-11 – 2009-06 · Lymphoma, Non Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
What this study did
NCT00396266 · Genzyme, a Sanofi Company
2005-01 – 2007-12 · Multiple Myeloma, Lymphoma, Non-Hodgkin
What this study did
NCT00396383 · Genzyme, a Sanofi Company
2004-11 – 2007-05 · Multiple Myeloma
What this study did
NCT00322842 · Genzyme, a Sanofi Company
2004-09 – 2007-02 · Lymphoma, Non-Hodgkin, Multiple Myeloma
What this study did
NCT00395967 · Genzyme, a Sanofi Company
2005-04 – 2006-08 · Multiple Myeloma, Lymphoma, Non-Hodgkin's
What this study did
NCT00322387 · Genzyme, a Sanofi Company
2004-04 – 2006-07 · Lymphoma, Non-Hodgkin, Multiple Myeloma
What this study did
NCT00322491 · Genzyme, a Sanofi Company
2004-03 – 2006-06 · Lymphoma, Non-Hodgkin, Multiple Myeloma
What this study did
Other / comorbidity
NCT07605416 · National Cancer Institute (NCI)
2027-04-20 – 2032-11-06 · Plasma Cell Leukemia
What this study did
NCT06872333 · Masonic Cancer Center, University of Minnesota
2024-11-19 – 2032-06-01 · Graft Failure, Sickle Cell Disease, Hemoglobinopathies
What this study did
NCT02015013 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-01-15 – 2030-10-31 · Idiopathic CD4-Positive, T-Lymphocytopenia
What this study did
NCT03055247 · IRCCS San Raffaele
2015-11-06 – 2026-07-18 · Chronic Granulomatous Disease X-linked (X-CGD)
What this study did
NCT06141304 · The First Hospital of Jilin University
2023-09-01 – 2025-07 · Relapsed Adult ALL, Relapsed Adult AML
What this study did
NCT01413100 · Fred Hutchinson Cancer Center
2011-09-15 – 2024-09-11 · Systemic Scleroderma
What this study did
NCT03746080 · Lawrence D Recht
2018-12-04 – 2024-02-08 · Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
What this study did
NCT04177810 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2020-11-16 – 2023-05-19 · Metastatic Pancreatic Cancer
What this study did
NCT04817345 · St. Jude Children's Research Hospital
2023-04 – 2023-04 · Sickle Cell Disease
What this study did
NCT05445128 · Ensoma
2022-06-24 – 2023-02-02 · Sickle Cell Disease
What this study did
NCT03547830 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2019-04-13 – 2023-01-01 · Chronic Granulomatous Disease
What this study did
NCT05411575 · 4Living Biotech
2022-07-19 – 2022-10 · COVID-19 Acute Respiratory Distress Syndrome, COVID-19
What this study did
NCT04762875 · Ensoma
2021-06-16 – 2022-03-14 · Related Donors Donating PBSC to a Family Member, Healthy Donors, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
What this study did
NCT02790957 · Gian Paolo Fadini
2016-06 – 2019-11 · Diabetes, Wounds, Critical Limb Ischemia
What this study did
NCT04058145 · Massachusetts General Hospital
2019-09-30 – 2019-10-11 · Head and Neck Cancer
What this study did
NCT03019809 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2016-06 – 2019-07 · Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation, Graft Failure
What this study did
NCT02931071 · Hospital Universitari Vall d'Hebron Research Institute
2013-09 – 2018-10 · Fanconi Anemia
What this study did
NCT03244930 · Hospital Universitario Dr. Jose E. Gonzalez
2017-05-10 – 2018-06-10 · Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin, Myeloma, Stem Cell Transplant Complications
What this study did
NCT01696461 · Center for International Blood and Marrow Transplant Research
2013-05 – 2016-08 · Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia
What this study did
NCT01818284 · M.D. Anderson Cancer Center
2013-10 – 2016-06 · Blood And Marrow Transplantation
What this study did
NCT02200380 · Celldex Therapeutics
2014-07 – 2016-04-13 · For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients, Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), Non-Hodgkins Lymphoma (NHL), Hodgkins Disease (HD), Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT01954914 · Technische Universität Dresden
2013-12 – 2016-01 · Blood Stem Cell Harvest Failure
What this study did
NCT01621477 · St. Jude Children's Research Hospital
2012-08 – 2015-12 · Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Hodgkin or Non-Hodgkin Lymphoma, Sarcoma, Myeloid
What this study did
NCT01403896 · Stephen Couban
2012-04 – 2015-12 · Malignant Lymphoma, Stem Cell Type
What this study did
NCT01164345 · Sheba Medical Center
2010-06 – 2015-05 · Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Stem Cell Mobilization, Autologous Stem Cell Transplantation
What this study did
NCT01746173 · Dana-Farber Cancer Institute
2013-07 – 2014-10 · T-cell Non-Hodgkin Lymphoma
What this study did
NCT01095757 · Emory University
2010-03 – 2014-02 · Myeloma, Lymphoma
What this study did
Phase 1/2 (30)
Multiple Myeloma
NCT00903968 · Dana-Farber Cancer Institute
2009-06-01 – 2016-10 · Multiple Myeloma
What this study did
NCT00241358 · Washington University School of Medicine
2004-05 – 2010-02 · Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic, Myelodysplastic Syndromes, Multiple Myeloma, Lymphoma, Non-Hodgkin, Hodgkin Disease
What this study did
Other / comorbidity
NCT06851767 · National Institute of Allergy and Infectious Diseases (NIAID)
2025-05-09 – 2034-12-31 · X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
What this study did
NCT07775313 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-10-21 – 2033-12-31 · WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, Myelokathexis
What this study did
NCT06325709 · National Institute of Allergy and Infectious Diseases (NIAID)
2024-04-17 – 2032-12-31 · Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease
What this study did
NCT06158828 · Washington University School of Medicine
2024-11-15 – 2030-05-31 · AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
What this study did
NCT07341022 · Hospital Israelita Albert Einstein
2026-06-01 – 2028-06 · Sickle Cell Disease
What this study did
NCT01318317 · City of Hope Medical Center
2011-10-20 – 2027-02-24 · Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
What this study did
NCT05357482 · National Heart, Lung, and Blood Institute (NHLBI)
2022-05-12 – 2027-01-31 · Sickle Cell Anemia, Beta Thalassemia
What this study did
NCT00967785 · National Institute of Allergy and Infectious Diseases (NIAID)
2010-01-06 – 2026-06-25 · Leukopenia, Neutropenia, Infections, Warts, Myelokathexis
What this study did
NCT03653247 · Sangamo Therapeutics
2019-03-06 – 2025-07-17 · Sickle Cell Disease
What this study did
NCT03182426 · University of Alberta
2017-08-15 – 2024-07-15 · Diabetes Mellitus, Type 1
What this study did
NCT03157804 · Hospital Infantil Universitario Niño Jesús, Madrid, Spain
2016-01-07 – 2023-09-08 · Fanconi Anemia
What this study did
NCT00669669 · Fred Hutchinson Cancer Center
2009-02-25 – 2021-01-20 · Glioblastoma, Gliosarcoma
What this study did
NCT02522572 · E. Steve Woodle
2015-08 – 2020-10 · Transplants and Implants
What this study did
NCT02678533 · Assistance Publique - Hôpitaux de Paris
2017-02-10 – 2019-05-03 · Fanconi Anemia
What this study did
NCT01977677 · Lawrence Recht
2014-11 – 2018-09 · Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglial Tumors, Adult Pineoblastoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
What this study did
NCT02212535 · Assistance Publique - Hôpitaux de Paris
2016-01-15 – 2017-09-27 · Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia
What this study did
NCT01288573 · Genzyme, a Sanofi Company
2014-03-03 – 2017-05-09 · Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, Brain Tumors
What this study did
NCT01435343 · PETHEMA Foundation
2012-07 – 2016-12 · Acute Myeloblastic Leukemia
What this study did
NCT01160354 · M.D. Anderson Cancer Center
2010-08 – 2016-03 · Acute Myelogenous Leukemia
What this study did
NCT00906945 · Washington University School of Medicine
2011-02 – 2015-09 · Leukemia, Myeloid, Acute
What this study did
NCT01280955 · Mitchell Horwitz, MD
2011-12 – 2015-05 · Failure of Bone Marrow Graft
What this study did
NCT00396968 · Genzyme, a Sanofi Company
— · Acute Myelogenous Leukemia, Myelodysplastic Syndromes
What this study did
NCT00733824 · Washington University School of Medicine
2008-11 – 2013-09 · Lymphoma, Non-Hodgkin, Hodgkin Disease
What this study did
NCT00822770 · M.D. Anderson Cancer Center
2009-01 – 2012-10 · Stem Cell Transplantation, Leukemia
What this study did
NCT00479115 · Children's Hospital Medical Center, Cincinnati
2007-05 – 2010-12 · Fanconi Anemia
What this study did
NCT00512252 · Washington University School of Medicine
2007-07 – 2010-06 · Leukemia, Myeloid, Acute
What this study did
Phase 1 (43)
Multiple Myeloma
NCT01526096 · University of Chicago
2011-07-12 – 2024-08-28 · Myeloma
What this study did
NCT03506802 · Jonsson Comprehensive Cancer Center
2018-07-10 – 2019-06-25 · HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT01610999 · Tufts Medical Center
2013-07 – 2015-12 · Chronic Lymphocytic Leukemia, Lymphoma, Multiple Myeloma
What this study did
NCT01074060 · City of Hope Medical Center
2010-04 – 2013-02 · Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
What this study did
Other / comorbidity
NCT06506461 · St. Jude Children's Research Hospital
2025-03-21 – 2032-12 · Sickle Cell Disease
What this study did
NCT07585136 · St. Jude Children's Research Hospital
2026-11 – 2029-07-01 · Bone Marrow Failure Syndrome
What this study did
NCT05088356 · Stanford University
2021-09-07 – 2028-05 · Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
What this study did
NCT05343572 · Hugh Taylor
2023-11-01 – 2027-12 · Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
What this study did
NCT03664830 · City of Hope Medical Center
2018-09-19 – 2027-07-06 · Sickle Cell Disease
What this study did
NCT06414889 · M.D. Anderson Cancer Center
2024-05-20 – 2027-06-30 · RUNX1 Familial Platelet Disorder
What this study did
NCT02193191 · Memorial Sloan Kettering Cancer Center
2014-09-17 – 2025-03-27 · Sickle Cell Disease
What this study did
NCT03612466 · Albert Einstein College of Medicine
2022-08 – 2024-09 · Osteosarcoma, Bone Metastases
What this study did
NCT01331018 · Fred Hutchinson Cancer Center
2012-02-22 – 2024-02-15 · Fanconi Anemia
What this study did
NCT03240861 · Jonsson Comprehensive Cancer Center
2017-07-26 – 2023-10-19 · HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
What this study did
NCT06892119 · Hospital Universitario Dr. Jose E. Gonzalez
2019-12-09 – 2020-11-30 · Lymphoma, Myeloma
What this study did
NCT02343666 · Fred Hutchinson Cancer Center
2016-08-15 – 2020-08-01 · Human Immunodeficiency Virus 1 Positive, Stage I Adult Hodgkin Lymphoma, Stage I Adult Non-Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult Non-Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Non-Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Non-Hodgkin Lymphoma
What this study did
NCT03277209 · Weill Medical College of Cornell University
2017-07-25 – 2019-12-30 · Pancreas Cancer
What this study did
NCT03226691 · National Heart, Lung, and Blood Institute (NHLBI)
2017-07-25 – 2019-02-27 · Sickle Cell Disease
What this study did
NCT02179970 · CCTU- Cancer Theme
2015-06 – 2018-12-14 · Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma, Colorectal Cancer Metastatic
What this study did
NCT02069080 · National Institute of Allergy and Infectious Diseases (NIAID)
2014-02-20 – 2018-07-10 · Cancer
What this study did
NCT01916577 · University of Colorado, Denver
2013-08 – 2017-12 · COPD, Cystic Fibrosis, Pulmonary Fibrosis
What this study did
NCT01339039 · Patrick Y. Wen, MD
2011-12 – 2017-04-08 · High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Mixed Anaplastic Oligoastrocytoma (AOA)
What this study did
NCT00943943 · M.D. Anderson Cancer Center
2010-10-29 – 2017-03-23 · Acute Myelogenous Leukemia, Leukemia
What this study did
NCT01352650 · Weill Medical College of Cornell University
2011-06-17 – 2016-12-27 · Acute Myeloid Leukemia
What this study did
NCT01065129 · Washington University School of Medicine
2010-09-02 – 2016-10-18 · Myelodysplastic Syndromes
What this study did
NCT01353937 · NYU Langone Health
2014-04 – 2016-09 · Diabetic Ulcer
What this study did
NCT01319864 · Seattle Children's Hospital
2011-03 – 2016-06-28 · Relapsed/Refractory AML, Relapsed/Refractory ALL, Secondary AML/MDS, Acute Leukemia of Ambiguous Lineage, AML, ALL
What this study did
NCT01026987 · Washington University School of Medicine
2010-04-29 – 2016-06-08 · Stem Cell Transplant Patients
What this study did
NCT01455025 · French Innovative Leukemia Organisation
2012-01 – 2015-08 · Acute Myeloid Leukemia
What this study did
NCT01373229 · David Rizzieri, MD
2012-01 – 2015-03 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT00322127 · National Heart, Lung, and Blood Institute (NHLBI)
2006-06-14 – 2015-01-23 · Healthy Volunteers
What this study did
NCT01655875 · Emory University
2012-06 – 2014-04 · Pediatric Acute Myeloblastic Leukemia, Relapsed, Pediatric Acute Lymphoblastic Leukemia, Relapsed
What this study did
NCT01068301 · St. Jude Children's Research Hospital
2010-05 – 2013-10 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
What this study did
NCT01711073 · Proteonomix, Inc.
2012-10 – 2013-09 · End Stage Liver DIsease
What this study did
NCT01802892 · GlaxoSmithKline
2012-11-02 – 2013-04-02 · Transplantation, Stem Cell
What this study did
NCT00990054 · Genzyme, a Sanofi Company
2009-12 – 2012-03 · Acute Myeloid Leukemia
What this study did
NCT01579149 · Genzyme, a Sanofi Company
2011-09 – 2012-02 · Healthy Volunteer
What this study did
NCT01027923 · Washington University School of Medicine
2010-05 – 2011-09 · Leukemia, Myeloid, Acute
What this study did
NCT00694590 · Genzyme, a Sanofi Company
2008-06 – 2011-09 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
NCT01058993 · University of Washington
2010-10 – 2011-04 · Neutropenia
What this study did
NCT00445302 · Genzyme, a Sanofi Company
2006-01 – 2007-08 · Renal Impairment
What this study did
Phase 4 (5)
Multiple Myeloma
NCT05087212 · Sanofi
2021-10-22 – 2022-12-30 · Autologous Haematopoietic Stem Cell Transplant
What this study did
Other / comorbidity
NCT05510544 · Peking University
2022-12-19 – 2024-01-31 · Lymphoma
What this study did
NCT02006225 · Tel-Aviv Sourasky Medical Center
2014-02 – 2020-02 · Autologous Stem Cell Transplantation
What this study did
NCT02056210 · University of Padova
2014-02 – 2014-10 · Diabetes
What this study did
NCT01164475 · Genzyme, a Sanofi Company
2010-10 – 2013-02 · Non-Hodgkin's Lymphoma
What this study did
Early phase / not applicable (6)
Multiple Myeloma
NCT01186224 · University of Liverpool
2010-05 – 2015-06 · Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoma, Lymphoproliferative Disorders
What this study did
NCT01042717 · Shi, Patricia, M.D.
2010-02 – 2011-12 · Multiple Myeloma, Non-Hodgkins Lymphoma
What this study did
NCT01076270 · Fred Hutchinson Cancer Center
2010-06 – 2011-02 · Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
What this study did
Other / comorbidity
NCT04045821 · Reproductive Medicine Associates of New Jersey
2020-01-17 – 2021-05-04 · Infertility of Uterine Origin
What this study did
NCT01408043 · Case Comprehensive Cancer Center
2011-10 – 2016-05 · Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT01206075 · University of Washington
2010-10 – 2014-12 · Beta-Thalassemia
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (3)
Multiple Myeloma
NCT06207799 · M.D. Anderson Cancer Center
2024-07-17 – 2031-12-31 · Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
What this study did
Other / comorbidity
NCT04362293 · St. Jude Children's Research Hospital
2020-04-30 – 2029-08-01 · Sickle Cell Disease
What this study did
NCT02570542 · Memorial Sloan Kettering Cancer Center
2015-10 – 2027-10 · Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Multiple Myeloma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Plerixafor: this drugApprovedSmall moleculeCXCR4Partial signal
NCT00103662: Collection of at least 6 x 10^6 CD34+ cells/kg in 2 or fewer aphereses: plerixafor plus G-CSF 71.6% (106/148) vs placebo plus G-CSF 34.4% (53/154), P<.001 (DiPersio et al., Blood 2009).
Belantamab MafodotinApprovedAntibody–drug conjugateBCMAPartial signal
NCT04246047: Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5)
NCT04162210: Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG) (Up to 27 months): Belantamab Mafodotin 11.2 Months (95% CI 6.4 to 14.5) vs Pomalidomide Plus Dexamethasone 7 Months (95% CI 4.6 to 10.6) missed
BortezomibApprovedSmall moleculeProteasomePartial signal
NCT00722566: Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73
NCT00048230: Response rate (CR+PR): 38% bortezomib vs 18% dexamethasone (P<0.001), with CR 6% vs <1%; median time to progression 6.22 vs 3.49 months (HR 0.55, P<0.001); 1-year survival 80% vs 66% (P=0.003), overall survival HR 0.57 (P=0.001).
CarfilzomibApprovedSmall moleculeProteasomePartial signal
NCT03158688: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants
NCT01568866: Progression-free Survival (From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively): Carfilzomib + DEX 18.7 months vs Bortezomib + DEX 9.4 months (95% CI 8.4 to 10.4)
Ciltacabtagene AutoleucelApprovedCell therapyBCMAPartial signal
NCT04181827: Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023).
DaratumumabApprovedMonoclonal antibodyCD38Partial signal
NCT03901963: Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS) (From randomization up to 12 months): Daratumumab + Lenalidomide 50.5% (95% CI 40.3 to 60.7) vs Lenalidomide 18.8% (95% CI 11.7 to 27.8)
NCT02076009: Progression-free survival at the interim analysis: hazard ratio 0.37 (95% CI 0.27 to 0.52; P<0.001); 12-month PFS 83.2% with daratumumab plus lenalidomide/dexamethasone vs 60.1% with lenalidomide/dexamethasone (POLLUX, N Engl J Med 2016).
ElotuzumabApprovedMonoclonal antibodySLAMF7 (CS1/CD319)Partial signal
NCT01335399: Progression-Free Survival (PFS) (From randomization to date of first documented tumor progression or death due to any cause (up to 8 years)): E-Ld Cohort 31.38 Months (95% CI 26.18 to 36.8) vs Ld Cohort 29.47 Months (95% CI 23.49 to 34.3) missed
NCT01239797: Median Progression Free Survival (PFS) (From randomization up to 326 events (up to approximately 38 months)): Lenalidomide + Dexamethasone + Elotuzumab 19.35 Months (95% CI 16.62 to 22.18) vs Lenalidomide + Dexamethasone 14.85 Months (95% CI 12.09 to 17.22)
ElranatamabApprovedMultispecific antibodyBCMA x CD3Weak signalFeatured results are non-efficacy only in this race
Iberdomide (Zenbexus)ApprovedSmall moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Idecabtagene VicleucelApprovedCell therapyBCMAReliable signal
NCT03651128: PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001)
NCT03361748: Overall Response Rate (From first dose to 24 Months): BB2121 74.5% (95% CI 67.1 to 81.8)
IsatuximabApprovedMonoclonal antibodyCD38Partial signal
NCT02990338: Progression Free Survival (PFS) (From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)): IPd (Isatuximab + Pomalidomide + Dexamethasone) 11.53 months (95% CI 8.936 to 13.897) vs Pd (Pomalidomide + Dexamethasone) 6.47 months (95% CI 4.468 to 8.279)
IxazomibApprovedSmall moleculeProteasomeReliable signal
NCT02312258: Progression Free Survival (PFS) (From randomization until PD or death (up to 52 months)): Ixazomib 17.4 months (95% CI 14.78 to 20.3) vs Placebo 9.4 months (95% CI 8.51 to 11.47)
NCT02181413: Progression Free Survival (PFS) (Randomization up to End of treatment (EOT) (24 months); thereafter followed up every 4 weeks (up to 45 months)): Ixazomib Citrate 26.5 months (95% CI 23.69 to 33.81) vs Placebo 21.3 months (95% CI 17.97 to 24.67)
LenalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligase, Thalidomide AnalogReliable signal
NCT00424047: Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (From randomization up to cut-off date of 03 August 2005; up to 24 months): Lenalidomide Plus Dexamethasone 52.1 weeks vs Placebo Plus Dexamethasone 20.1 weeks (95% CI 16.6 to 20.7)
NCT00056160: Time to Tumor Progression (TTP) (60 weeks (median Time To Progression of CC-5013/Dex treatment group)): CC-5013/Dex 60.1 Weeks (95% CI 41.1 to 80) vs Placebo/Dex 20.1 Weeks (95% CI 16.1 to 21.1)
LinvoseltamabApprovedMultispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Melphalan Hydrochloride (Evomela)ApprovedSmall moleculeDNA (guanine N7 position)Weak signal
NCT03159702: Progression-free Survival (PFS) of Participants With Hematological Malignancies Undergoing Treatment. (1 year): MEL/FLU and Total-Body Irradiation (TBI) 17/43
MotixafortideApprovedPeptideCXCR4Partial signal
NCT03246529: Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel).
NCT02639559: Number of Donors That Mobilize ≥ 2 x 10^6 CD34+ Cells/kg of Recipients Weight After a Single Injection of BL-8040 After no More Than Two Leukapheresis Collections (Arm 1 - Donors Only) (Up to Day 2): Arm 1: Donors 22/24
PomalidomideApprovedSmall moleculeCereblon (CRBN)Partial signal
NCT01324947: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment (From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.): Pomalidomide 23%
NCT01311687: Progression-free Survival (PFS) - Primary Analysis (From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.): Pomalidomide Plus Low-Dose Dexamethasone 15.7 weeks (95% CI 13 to 20.1) vs High-Dose Dexamethasone 8 weeks (95% CI 7 to 9)
SelinexorApprovedSmall moleculeXPO1 (exportin-1)Partial signal
NCT03110562: SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78)
TalquetamabApprovedMultispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
TeclistamabApprovedMultispecific antibodyBCMA x CD3Partial signal
NCT05083169: Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16).
NCT04696809: Phase 2 primary endpoint ORR 76.9% (>=VGPR 76.9%, >=CR 65.4%) in 26 patients at RP2D 1.5 mg/kg; median follow-up 14.32 months
ThalidomideApprovedSmall moleculeCereblon E3 ubiquitin-ligasePartial signalFeatured results are non-efficacy only in this race
Zoledronic Acid (Zometa)ApprovedSmall moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
PanobinostatUS approval withdrawnSmall moleculeHDACPartial signal
NCT01023308: Progression-free survival (investigator-assessed): median 11.99 months with panobinostat + bortezomib + dexamethasone vs 8.08 months with placebo + bortezomib + dexamethasone; HR 0.63 (95% CI 0.52-0.76), p<0.0001 (Lancet Oncology 2014)
Anitocabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
Arlocabtagene AutoleucelPhase 3Cell therapyGPRC5DWeak signalFeatured results are safety only in this race
AZD0120Phase 3Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
BCD-264Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 3Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CT-P44Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLReliable signal
NCT01345019: Time to First On-study Skeletal Related Event (From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.): Denosumab 695 days vs Zoledronic Acid 730 days (95% CI 504 to 1014)
Equecabtagene AutoleucelPhase 3Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
EtentamigPhase 3Multispecific antibodyBCMA x CD3Partial signal
NCT06158841: Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03).
F182112Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
FelzartamabPhase 3Monoclonal antibodyCD38Partial signal
NCT03952091: Median PFS: 18·9 months felzartamab+Rd vs 10·4 months Rd (hazard ratio 0·62; p=0·0035)
Gamgertamig (CM336)Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
HLX15Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
IBI3003Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
InobrodibPhase 3Small moleculeCBP/p300 (bromodomain)not yet gradedNo reviewed efficacy summary in this indication
LumrotatugPhase 3Monoclonal antibodyCD38Weak signal
NCT04818372: CM313 phase 1 dose-escalation/expansion (NCT04818372, anti-CD38 mAb, R/R multiple myeloma + marginal zone lymphoma): grade>=3 TEAEs 15/34 (44.1%), no DLTs; ORR 34.5% among 29 evaluable RRMM patients; median PFS 132 days.
MezigdomidePhase 3Small moleculeCereblon E3 ubiquitin-ligasePartial signal
NCT05552976: Primary endpoint, progression-free survival: statistically significant and clinically meaningful improvement vs carfilzomib and dexamethasone (Bristol Myers Squibb, 2026-03-09).
PlitidepsinPhase 3Small moleculeeEF1A2 (eukaryotic translation elongation factor 1-alpha 2)Partial signal
NCT01102426: Progression Free Survival (PFS) as Per Intention-to-treat (ITT) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years): Plitidepsin+Dexamethasone 2.6 months (95% CI 1.9 to 3) vs Dexamethasone 1.7 months (95% CI 1.1 to 2)
QL2109Phase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
QLS32015Phase 3Multispecific antibodyGPRC5D x CD3not yet gradedNo reviewed efficacy summary in this indication
QLS4131Phase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
RamantamigPhase 3Multispecific antibodyGPRC5D x BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
SanritatugPhase 3Monoclonal antibodyCD38not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 3Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
TorutamigPhase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
TQB2934Phase 3Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
Velinotamig (GR1803)Phase 3Multispecific antibodyBCMA x CD3Weak signalNo reviewed efficacy summary in this indication
VenetoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
Burixafor (TG-0054)Phase 2Small moleculeCXCR4Weak signal
NCT01458288: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5
NCT01018979: Primary mobilization success: 2/4 patients in the TG-0054 2.24 mg/kg group (MM 1, NHL 1) vs 1/3 patients in the 3.14 mg/kg group (MM 1); no p-value or confidence interval reported.
CemsidomidePhase 2Small moleculeCereblon E3 ubiquitin-ligasenot yet gradedNo reviewed efficacy summary in this indication
Hrain Anti-BCMA CAR-TPhase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
HRC0202Phase 2Cell therapyBCMAWeak signalFeatured results are safety only in this race
Iopofosine I-131Phase 2Radiopharmaceuticalphospholipid ether (selective lipid raftWeak signal
NCT02278315: The phase 1 dose-escalation and safety study enrolled 31 patients with relapsed or refractory multiple myeloma who had received a median of four prior lines of therapy. It established 31.25 mCi/m2 as the maximum tolerated single dose and identified 20 mCi/m2 administered twice, one week apart, as the highest evaluated fractionated dose regimen.
LMY-920Phase 2Cell therapyBCMA / TACInot yet gradedNo reviewed efficacy summary in this indication
RAPA-201Phase 2Cell therapyRapamycin-resistant autologous T-cell therapyWeak signal
NCT04176380: Overall response rate: 9/14 patients (64%) achieved disease remission (IMWG criteria) - 8 partial responses, 1 stringent complete response.
YKST02Phase 2Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD4045Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BCMA CAR-NK (Shenzhen Pregene Biopharma)Phase 1/2Cell therapyBCMAWeak signalNo reviewed efficacy summary in this indication
BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech)Phase 1/2Cell therapyBCMAnot yet gradedNo reviewed efficacy summary in this indication
BelantamabPhase 1/2Monoclonal antibodyBCMAnot yet gradedNo reviewed efficacy summary in this indication
AD-214
Phase 1(overall)
Antibody-derived scaffoldCXCR4
Weak signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 63 furthest-along competitors are listed; 105 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(15 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Plerixafor to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation FailureRecruiting
Est. primary completion 2026-12 · NCT05343572 · CT.gov ↗
What to watch
2027 (4)
June 2027 (1)
Phase 1RUNX1 Familial Platelet DisorderRecruiting
Est. primary completion 2027-06-30 · NCT06414889 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1Sickle Cell DiseaseActive not recruiting
Est. primary completion 2027-07-06 · NCT03664830 · CT.gov ↗
What to watch
Phase 1/2HIV, Hematologic MalignanciesRecruiting
Est. primary completion 2027-07-30 · NCT05470491 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Sickle Cell DiseaseNot yet recruiting
Est. primary completion 2027-12 · NCT07341022 · CT.gov ↗
What to watch
2028 (3)
May 2028 (1)
Phase 1Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia …Active not recruiting
Est. primary completion 2028-05 · NCT05088356 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09-15 · NCT06158828 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1Bone Marrow Failure SyndromeRecruiting
Est. primary completion 2028-12-01 · NCT07585136 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 1Sickle Cell DiseaseRecruiting
Est. primary completion 2029-12 · NCT06506461 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 2Graft Failure, Sickle Cell Disease, HemoglobinopathiesRecruiting
Est. primary completion 2030-06-01 · NCT06872333 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Idiopathic CD4-Positive, T-LymphocytopeniaRecruiting
Est. primary completion 2030-10-31 · NCT02015013 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 1/2WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency, MyelokathexisEnrolling by invitation
Est. primary completion 2031-12-31 · NCT07775313 · CT.gov ↗
What to watch
2032 (2)
November 2032 (1)
Phase 2Plasma Cell LeukemiaRecruiting
Est. primary completion 2032-11-06 · NCT07605416 · CT.gov ↗
What to watch
December 2032 (1)
Phase 1/2Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous DiseaseRecruiting
Est. primary completion 2032-12-31 · NCT06325709 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 1/2X-linked Severe Combined Immunodeficiency, X-SCID, XSCIDEnrolling by invitation
Est. primary completion 2034-12-31 · NCT06851767 · CT.gov ↗
What to watch

See the full readout calendar ↗